TREATMENT PATTERNS AND OUTCOMES OF ACTHAR GEL IN SYSTEMIC LUPUS ERYTHEMATOSUS: A PHYSICIAN-REPORTED CHART REVIEW
Notice bibliographique
Résumé
PV271 / #799 Poster Topic: AS24 - SLE-Treatment Background/Purpose Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides. Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several autoimmune disorders and medical conditions known to cause inflammation, including systemic lupus erythematosus (SLE). This study aims to describe the characteristics of patients with SLE treated with Acthar Gel, utilization patterns of the medication, and physicians’ assessments of its effects on patients’ health status. Methods This study was prospectively designed with a predefined protocol and statistical analysis plan. The study employed a chart review methodology, where 41 U.S. rheumatologists reviewed 56 patient charts for individuals treated with Acthar Gel for SLE within the past 24 months. Patients with known contraindications to Acthar Gel were excluded from the study. In November 2024, physicians searched patient records starting from April 1, 2022. Data included demographics, comorbidities, symptoms, prior treatments and health outcomes following Acthar Gel treatment. Results The study included 56 SLE patients with an average age of 42 years and mean BMI of 27.5 kg/m 2 . Most were female (84%) and African American (50%). Common comorbidities included chronic joint disease (34%), hyperlipidemia (34%), hypertension (34%) and arthritis/osteoarthritis (30%). Prior to Acthar Gel treatment, 63% of patients reported fair-to-poor health status, with a mean rating of 3.6 out of 5 (where 1 = excellent and 5 = poor). Frequent symptoms included joint pain (84%), rashes (68%) and fatigue (68%). Most were previously treated with antimalarial drugs (64%), corticosteroids (64%), immunosuppressive drugs (57%) and biologic disease-modifying antirheumatic drugs (DMARDs) (55%). The average time since diagnosis was 4.8 years and the average duration of Acthar Gel treatment was 8 months. Most patients (91%) were dosed at 40-80 units twice per week. Physicians reported that 89% of patients experienced improved health status after Acthar Gel treatment. Improvements among these patients included overall symptoms (82%), pain (54%), fatigue (44%), reduced corticosteroid use (44%), physical function (38%) and strength (28%). Conclusions This study demonstrates that Acthar Gel is an effective treatment option for SLE. Patients experienced improvements in multiple areas such as symptoms, pain relief, fatigue, reduced corticosteroid use, physical function and strength. These findings underscore the utility of Acthar Gel in enhancing outcomes for patients with SLE.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».